Your browser doesn't support javascript.
loading
TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians.
Schoretsanitis, Georgios; Paulzen, Michael; Unterecker, Stefan; Schwarz, Markus; Conca, Andreas; Zernig, Gerald; Gründer, Gerhard; Haen, Ekkerhard; Baumann, Pierre; Bergemann, Niels; Clement, Hans Willi; Domschke, Katharina; Eckermann, Gabriel; Egberts, Karin; Gerlach, Manfred; Greiner, Christine; Havemann-Reinecke, Ursula; Hefner, Gudrun; Helmer, Renate; Janssen, Ger; Jaquenoud-Sirot, Eveline; Laux, Gerd; Messer, Thomas; Mössner, Rainald; Müller, Matthias J; Pfuhlmann, Bruno; Riederer, Peter; Saria, Alois; Schoppek, Bernd; Silva Gracia, Margarete; Stegmann, Benedikt; Steimer, Werner; Stingl, Julia C; Uhr, Manfred; Ulrich, Sven; Waschgler, Roland; Zurek, Gabriela; Hiemke, Christoph.
Affiliation
  • Schoretsanitis G; a Department of Psychiatry , University of Bern , Bern , Switzerland.
  • Paulzen M; b Department of Psychiatry, Psychotherapy and Psychosomatics , RWTH Aachen University, JARA - Translational Brain Medicine , Aachen , Germany.
  • Unterecker S; b Department of Psychiatry, Psychotherapy and Psychosomatics , RWTH Aachen University, JARA - Translational Brain Medicine , Aachen , Germany.
  • Schwarz M; c Alexianer Hospital Aachen , Aachen , Germany.
  • Conca A; d Department of Psychiatry, Psychosomatics and Psychotherapy , University Hospital of Würzburg , Germany.
  • Zernig G; e Department of Laboratory Medicine , Ludwig Maximilian University , Munich , Germany.
  • Gründer G; f Servizio Psichiatrico del Comprensorio Sanitario di Bolzano , Bolzano , Italy.
  • Haen E; g Experimental Psychiatry Unit, Department of Psychiatry and Psychotherapy , Medical University of Innsbruck , Innsbruck , Austria.
  • Baumann P; h Private Practice for Psychotherapy and Court-Certified Witness , Hall in Tirol , Austria.
  • Bergemann N; i Department of Molecular Neuroimaging , Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg , Mannheim , Germany.
  • Clement HW; j Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology , University of Regensburg , Regensburg , Germany.
  • Domschke K; k Department of Psychiatry , University of Lausanne , Lausanne , Switzerland.
  • Eckermann G; l Kitzberg Hospitals, Center for Psychosomatic Medicine and Psychotherapy , Bad Mergentheim , Germany.
  • Egberts K; m Department of Child and Adolescent Psychiatry , University of Freiburg , Freiburg , Germany.
  • Gerlach M; n Department of Psychiatry and Psychotherapy , Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg , Germany.
  • Greiner C; o Psychiatric Hospital , Kaufbeuren , Germany.
  • Havemann-Reinecke U; p Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy , Center of Mental Health, University Hospital of Würzburg , Germany.
  • Hefner G; p Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy , Center of Mental Health, University Hospital of Würzburg , Germany.
  • Helmer R; q Federal Institute for Drugs and Medical Devices (BfArM) , Bonn , Germany.
  • Janssen G; r Department of Psychiatry and Psychosomatics , University of Göttingen , Göttingen , Germany.
  • Jaquenoud-Sirot E; s Psychiatric Hospital, Vitos Klinik Hochtaunus , Friedrichsdorf , Germany.
  • Laux G; t Center of Epilepsy , Bielefeld , Germany.
  • Messer T; u Medical Laboratory Stein , Limbach Group , Mönchengladbach , Germany.
  • Mössner R; v Psychiatric Hospital , Brugg , Switzerland.
  • Müller MJ; w Institute of Psychological Medicine , Haag in Oberbayern , Germany.
  • Pfuhlmann B; x Danuviuskliniken, Psychiatric Hospital , Pfaffenhofen , Germany.
  • Riederer P; y Department of Psychiatry and Psychotherapy , University of Tübingen , Tübingen , Germany.
  • Saria A; z Psychiatric Hospitals Oberberggruppe , Berlin , Germany.
  • Schoppek B; aa Psychiatric Hospital Weisser Hirsch , Dresden , Germany.
  • Silva Gracia M; d Department of Psychiatry, Psychosomatics and Psychotherapy , University Hospital of Würzburg , Germany.
  • Stegmann B; g Experimental Psychiatry Unit, Department of Psychiatry and Psychotherapy , Medical University of Innsbruck , Innsbruck , Austria.
  • Steimer W; ab kbo-Isar-Amper Klinikum München-Ost, Psychiatric Hospital , Munich , Germany.
  • Stingl JC; j Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology , University of Regensburg , Regensburg , Germany.
  • Uhr M; j Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology , University of Regensburg , Regensburg , Germany.
  • Ulrich S; ac Institute of Clinical Chemistry and Pathobiochemistry, Technical University Munich , Munich , Germany.
  • Waschgler R; q Federal Institute for Drugs and Medical Devices (BfArM) , Bonn , Germany.
  • Zurek G; ad Max Planck Institute of Psychiatry , Munich , Germany.
  • Hiemke C; ae Aristo Pharma GmbH , Berlin , Germany.
World J Biol Psychiatry ; 19(3): 162-174, 2018 04.
Article in En | MEDLINE | ID: mdl-29493375
ABSTRACT

OBJECTIVES:

Therapeutic drug monitoring (TDM) combines the quantification of drug concentrations in blood, pharmacological interpretation and treatment guidance. TDM introduces a precision medicine tool in times of increasing awareness of the need for personalized treatment. In neurology and psychiatry, TDM can guide pharmacotherapy for patient subgroups such as children, adolescents, pregnant women, elderly patients, patients with intellectual disabilities, patients with substance use disorders, individuals with pharmacokinetic peculiarities and forensic patients. Clear indications for TDM include lack of clinical response in the therapeutic dose range, assessment of drug adherence, tolerability issues and drug-drug interactions.

METHODS:

Based upon existing literature, recommended therapeutic reference ranges, laboratory alert levels, and levels of recommendation to use TDM for dosage optimization without specific indications, conversion factors, factors for calculation of dose-related drug concentrations and metabolite-to-parent ratios were calculated.

RESULTS:

This summary of the updated consensus guidelines by the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie offers the practical and theoretical knowledge for the integration of TDM as part of pharmacotherapy with neuropsychiatric agents into clinical routine.

CONCLUSIONS:

The present guidelines for TDM application for neuropsychiatric agents aim to assist clinicians in enhancing safety and efficacy of treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychiatry / Psychopharmacology / Drug Monitoring / Practice Guidelines as Topic / Consensus / Neurology Type of study: Guideline Limits: Humans Language: En Journal: World J Biol Psychiatry Journal subject: PSIQUIATRIA Year: 2018 Document type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psychiatry / Psychopharmacology / Drug Monitoring / Practice Guidelines as Topic / Consensus / Neurology Type of study: Guideline Limits: Humans Language: En Journal: World J Biol Psychiatry Journal subject: PSIQUIATRIA Year: 2018 Document type: Article Affiliation country: Switzerland